In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer-Vicuron: Fill Pipeline, Minimize R&D Expense

Executive Summary

The Vicuron acquisition auction, won by Pfizer, starkly revealed the fact that the biggest Big Pharmas have now got a striking advantage in their ability to access new products. Not only do they have more cash than anyone else, they can spend it without hurting the "adjusted" profits they highlight to Wall Street. As importantly, investors don't punish them on the basis of the expected returns from these investments. Indeed, the market expects them to spend the money-for now.
Advertisement

Related Content

Will a New Accounting Change Cut Acquisition Values?
Reviewing 2005: The Top Biopharma Stories
Move Over Late-Stage Alliances; Enter Acquisitions
Deal Statistics Quarterly, Q2 2005
Pfizer Trims Altana From Pipeline
Double Blow to Branded Firms
Licensing Vivitrex: A Win for the Mid-sized Pharma and Specialists
Double Blow to Branded Firms
A Recipe for Acquisition: the Esperion Strategy
A Recipe for Acquisition: the Esperion Strategy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel